Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 3
Submit an article Journal homepage
425
Views
49
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

C. Tom KouroukisJuravinski Hospital and Cancer Centre, Hamilton, Ontario, CanadaCorrespondence[email protected]
,
Louis A. V. FernandezQEII Health Sciences Centre, Halifax, Nova Scotia, Canada
,
Michael CrumpUniversity Health Network, Toronto, Ontario, Canada
,
Neil Sun ChuaCross Cancer Institute, Edmonton, Alberta, Canada
,
Rena BucksteinOdette Cancer Centre, Toronto, Ontario, Canada
,
Robert TurnerCross Cancer Institute, Edmonton, Alberta, Canada
,
Sarit AssoulineJewish General Hospital, Montreal, Quebec, Canada
,
Richard J. KlasaBC Cancer Agency, Vancouver, British Columbia, Canada
,
Wendy WalshNCIC Clinical Trials Group, Kingston, Ontario, Canada
,
Jean PowersNCIC Clinical Trials Group, Kingston, Ontario, Canada
&
Elizabeth EisenhauerNCIC Clinical Trials Group, Kingston, Ontario, Canada
 show all
Pages 394-399 | Received 26 Aug 2010, Accepted 04 Dec 2010, Published online: 16 Feb 2011

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Tadeusz Robak, Piotr Smolewski, Pawel Robak & Martin Dreyling. (2019) Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leukemia & Lymphoma 60:11, pages 2622-2634.
Read now
Mohamad Bassam Sonbol, Talal Hilal, Amylou C. Dueck, Allison C. Rosenthal, Christopher R. Conley, Heidi E. Kosiorek, Brenda F. Ginos, Katherine M. Gano, Craig S. Nichols, Jose F. Leis, Patrick B. Johnston, Thomas M. Habermann, Donald W. Northfelt, Peter Leif Bergsagel, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell & Craig B. Reeder. (2018) A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia & Lymphoma 59:9, pages 2128-2134.
Read now
Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Hess, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, Carlo Visco, Jan Walewski, Francesco Zaja & Pier Luigi Zinzani. (2018) Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia & Lymphoma 59:8, pages 1814-1828.
Read now
Richard Arkwright, Tri Minh Pham, Jeffrey A. Zonder & Q. Ping Dou. (2017) The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Drug Discovery 12:2, pages 225-235.
Read now
Nishanth Vallumsetla, Jonas Paludo & Prashant Kapoor. (2015) Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Therapeutics and Clinical Risk Management 11, pages 1663-1674.
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Danyu Sun & Mitchell R Smith. (2014) Bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Orphan Drugs 2:11, pages 1233-1241.
Read now
Prithviraj Bose, Michael S Batalo, Beata Holkova & Steven Grant. (2014) Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 15:16, pages 2443-2459.
Read now
Francesco Zaja, Massimo Federico, Umberto Vitolo & Pier Luigi Zinzani. (2014) Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Leukemia & Lymphoma 55:5, pages 988-998.
Read now
Valérie Camara-Clayette, Olivier Hermine & Vincent Ribrag. (2012) Emerging agents for the treatment of mantle cell lymphoma. Expert Review of Anticancer Therapy 12:9, pages 1205-1215.
Read now
Simon Rule. (2011) Velcade combinations in mantle cell lymphoma: are we learning anything?. Leukemia & Lymphoma 52:4, pages 545-547.
Read now

Articles from other publishers (38)

Diego Villa, Roopesh Kansara, Christopher Lemieux & John Kuruvilla. (2022) Updates in the treatment of mantle cell lymphoma: A Canadian expert framework. Canadian Hematology Today.
Crossref
Nishant Kumar Ojha, Jingjing Liu, Tianqi Yu, Chengxiu Fang, Jiyong Zhou & Min Liao. (2021) Interplay of the ubiquitin proteasome system and the innate immune response is essential for the replication of infectious bronchitis virus. Archives of Virology 166:8, pages 2173-2185.
Crossref
G.R. Tundo, D. Sbardella, A.M. Santoro, A. Coletta, F. Oddone, G. Grasso, D. Milardi, P.M. Lacal, S. Marini, R. Purrello, G. Graziani & M. Coletta. (2020) The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacology & Therapeutics 213, pages 107579.
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2020) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 153, pages 103038.
Crossref
Maria A. Kasherman, Susitha Premarathne, Thomas H. J. Burne, Stephen A. Wood & Michael Piper. (2020) The Ubiquitin System: a Regulatory Hub for Intellectual Disability and Autism Spectrum Disorder. Molecular Neurobiology 57:5, pages 2179-2193.
Crossref
Pawel Robak & Tadeusz Robak. (2019) Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs in R&D 19:2, pages 73-92.
Crossref
Pamela McKay, Mike Leach, Bob Jackson, Stephen Robinson & Simon Rule. (2018) Guideline for the management of mantle cell lymphoma. British Journal of Haematology 182:1, pages 46-62.
Crossref
Sudjit Luanpitpong, Nawin Chanthra, Montira Janan, Jirarat Poohadsuan, Parinya Samart, Yaowalak U-Pratya, Yon Rojanasakul & Surapol Issaragrisil. (2018) Inhibition of O -GlcNAcase Sensitizes Apoptosis and Reverses Bortezomib Resistance in Mantle Cell Lymphoma through Modification of Truncated Bid . Molecular Cancer Therapeutics 17:2, pages 484-496.
Crossref
Margot S. F. Roeten, Jacqueline Cloos & Gerrit Jansen. (2017) Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemotherapy and Pharmacology 81:2, pages 227-243.
Crossref
Linda Sooman, Joachim Gullbo, Michael Bergqvist, Stefan Bergström, Johan Lennartsson & Simon Ekman. (2017) Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. BMC Research Notes 10:1.
Crossref
Mukundan Baskar Mannargudi & Subrata Deb. (2017) Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?. Journal of Cancer Research and Clinical Oncology 143:8, pages 1499-1529.
Crossref
Sai Ravi Pingali & Timothy S. Fenske. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants 402 416 .
. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants 361 444 .
Rui Zhu, Dan Lu, Yu-Waye Chu, Akiko Chai, Michelle Green, Nancy Zhang & Jin Yan Jin. (2017) Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. The AAPS Journal 19:3, pages 669-681.
Crossref
Erden Atilla, Pinar Ataca Atilla & Taner Demirer. (2016) Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?. International Journal of Hematology 105:3, pages 257-264.
Crossref
Bryan Hambley, Paolo F. Caimi & Basem M. William. (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology 7:4, pages 196-208.
Crossref
Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh. (2016) Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget 7:30, pages 48692-48731.
Crossref
Areumnuri Kim, Ki Moon Seong, Hye Jin Kang, Sunhoo Park & Seung-Sook Lee. (2015) Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Oncotarget 6:35, pages 38225-38238.
Crossref
Tadeusz Robak. (2015) Bortezomib in the treatment of mantle cell lymphoma. Future Oncology 11:20, pages 2807-2818.
Crossref
Anita Kumar. (2015) Novel Agents in Mantle Cell Lymphoma. Current Oncology Reports 17:8.
Crossref
Alberto Mussetti, Anita Kumar, Parastoo B. Dahi, Miguel-Angel Perales & Craig S. Sauter. (2015) Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Reviews 29:3, pages 143-152.
Crossref
Michał Szymczyk. (2015) Chłoniak z komórek płaszcza – nawrót po leczeniu pierwszej linii. Acta Haematologica Polonica 46:2, pages 112-117.
Crossref
Elias Campo & Simon Rule. (2015) Mantle cell lymphoma: evolving management strategies. Blood 125:1, pages 48-55.
Crossref
Annete Njue, Ann Colosia, Peter C. Trask, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Police, Jianmin Wang, Rodrigo Ruiz-Soto, James A. Kaye & Farrukh Awan. (2015) Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma Myeloma and Leukemia 15:1, pages 1-12.e7.
Crossref
Simone Ferrero & Martin Dreyling. 2015. Management of Hematological Cancer in Older People. Management of Hematological Cancer in Older People 143 168 .
M Dreyling, S Ferrero & O Hermine. (2014) How to manage mantle cell lymphoma. Leukemia 28:11, pages 2117-2130.
Crossref
M. Dreyling, C. Geisler, O. Hermine, H.C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto. (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 25, pages iii83-iii92.
Crossref
Andrew M. Evens, Steven T. Rosen, Irene Helenowski, Justin Kline, Annette Larsen, Jennifer Colvin, Jane N. Winter, Koen M. van Besien, Leo I. Gordon & Sonali M. Smith. (2013) A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. British Journal of Haematology 163:1, pages 55-61.
Crossref
Simone Ferrero & Martin Dreyling. (2013) The current therapeutic scenario for relapsed mantle cell lymphoma. Current Opinion in Oncology 25:5, pages 452-462.
Crossref
Antonino Carbone & Anas YounesKathrin Aprile von HohenstaufenAlden MocciaEmanuele Zucca. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies 232 249 .
Carlo ViscoSilvia FinottoRenato ZambelloRossella PaoliniAndrea MeninRoberta ZanottiFrancesco ZajaGianpietro SemenzatoGiovanni PizzoloEmanuele S.G. D'AmoreFrancesco Rodeghiero. (2013) Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology 31:11, pages 1442-1449.
Crossref
Min Shen & Q. Ping Dou. 2013. Cell Death Signaling in Cancer Biology and Treatment. Cell Death Signaling in Cancer Biology and Treatment 303 329 .
P. McKay, M. Leach, R. Jackson, G. Cook & S. Rule. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology 159:4, pages 405-426.
Crossref
Bijal D. Shah, Peter MartinEduardo M. Sotomayor. (2012) Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches. Cancer Control 19:3, pages 227-235.
Crossref
Yogesh A. Karpe & Xiang-Jin Meng. (2012) Hepatitis E Virus Replication Requires an Active Ubiquitin-Proteasome System. Journal of Virology 86:10, pages 5948-5952.
Crossref
Anthony R. Mato, Tatyana Feldman & André Goy. (2012) Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside. The Oncologist 17:5, pages 694-707.
Crossref
Mariola J. Edelmann, Benjamin Nicholson & Benedikt M. Kessler. (2011) Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Reviews in Molecular Medicine 13.
Crossref
Stéphanie Harel, Richard Delarue, Vincent Ribrag, Martin Dreyling & Olivier Hermine. (2011) Treatment of Younger Patients With Mantle Cell Lymphoma. Seminars in Hematology 48:3, pages 194-207.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.